| (−) Deprenyl and (−) 1-phenyl-2-propylaminopentane,[(−) PPAP] act primarily as potent stimulants of action potential—transmitter release coupling in the catecholaminergic neurons J Knoll, I Miklya, B Knoll, R Markó, K Kelemen Life Sciences 58 (10), 817-827, 1996 | 67 | 1996 |
| Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-) deprenyl (selegiline) medication J Knoll, I Miklya Life Sciences 56 (8), 611-620, 1995 | 67 | 1995 |
| (−) 1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane,[(−) BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain J Knoll, F Yoneda, B Knoll, H Ohde, I Miklya British journal of pharmacology 128 (8), 1723-1732, 1999 | 64 | 1999 |
| Sexually low performing male rats die earlier than their high performing peers and (-) deprenyl treatment eliminates this difference J Knoll, TT Yen, I Miklya Life Sciences 54 (15), 1047-1057, 1994 | 60 | 1994 |
| Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain J Knoll, I Miklya, B Knoll, R Markó, D Rácz Life sciences 58 (23), 2101-2114, 1996 | 59 | 1996 |
| Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives S Shimazu, I Miklya Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (3), 421-427, 2004 | 52 | 2004 |
| Structure–activity studies leading to (−) 1-(Benzofuran-2-yl)-2-propylaminopentane,((−) BPAP), a highly potent, selective enhancer of the impulse propagation mediated release … F Yoneda, T Moto, M Sakae, H Ohde, B Knoll, I Miklya, J Knoll Bioorganic & medicinal chemistry 9 (5), 1197-1212, 2001 | 50 | 2001 |
| Sexual hormones terminate in the rat the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period J Knoll, I Miklya, B Knoll, J Dalló Life Sciences 67 (7), 765-773, 2000 | 48 | 2000 |
| Multiple, small dose administration of (-) deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to … J Knoll, I Miklya Archives internationales de pharmacodynamie et de therapie 328 (1), 1-15, 1994 | 44 | 1994 |
| The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015) I Miklya Molecular psychiatry 21 (11), 1499-1503, 2016 | 42 | 2016 |
| The role of parkin in Parkinson's disease I Miklya, P Göltl, F Hafenscher, N Pencz Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet …, 2014 | 35 | 2014 |
| Analysis of the analgesic and anti-inflammatory effects of rimazolium, a pyrido-pyrimidine derivative, compared with that of prostaglandin synthesis inhibitors and morphine. K Gyires, S Fürst, I Miklya, I Budavari, J Knoll Drugs under experimental and clinical research 11 (8), 493-500, 1985 | 27 | 1985 |
| A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), α-tocopherol was ineffective in the DATATOP study I Miklya, B Knoll, J Knoll Life sciences 72 (23), 2641-2648, 2003 | 20 | 2003 |
| Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane,(−)-BPAP J Knoll, I Miklya, B Knoll Life sciences 71 (18), 2137-2144, 2002 | 20 | 2002 |
| High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers J Knoll, B Knoll, I Miklya Life sciences 58 (11), 945-952, 1996 | 19 | 1996 |
| Major depression and the synthetic enhancer substances,(−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane P Gaszner, I Miklya Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (1), 5-14, 2006 | 18 | 2006 |
| Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) J Knoll, I Miklya Life Sciences 167, 32-38, 2016 | 17 | 2016 |
| The role of alpha-synuclein in Parkinson's disease I Miklya, N Pencz, F Hafenscher, P Göltl Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet …, 2014 | 17 | 2014 |
| Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain I Miklya, J Knoll Life sciences 72 (25), 2915-2921, 2003 | 17 | 2003 |
| A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain J Knoll, K Baghy, S Eckhardt, P Ferdinandy, M Garami, LG Harsing Jr, ... Life Sciences 182, 57-64, 2017 | 11 | 2017 |
Joseph KnollSemmelweis University, Department of Pharmacology and PharmacotherapyVerified email at net.sote.hu
